# OnCo record wilms-risk-markers (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/wilms-risk-markers/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "wilms-risk-markers" ;
  schema:name "Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)"@en ;
  schema:alternateName "anaplastic Wilms tumour"@en, "diffuse anaplasia"@en, "focal anaplasia"@en, "favourable histology Wilms tumour"@en, "unfavourable histology"@en, "1p/16q loss of heterozygosity"@en, "LOH 1p and 16q"@en, "1q gain in Wilms tumour"@en, "blastemal-type Wilms tumour"@en, "SIOP risk group"@en, "SIOP UMBRELLA"@en, "COG renal tumour risk group"@en, "very low risk Wilms tumour"@en, "bilateral Wilms tumour"@en, "nephrogenic rests"@en, "11p15 loss of heterozygosity"@en ;
  schema:description "Wilms tumour is cured in nine of ten children, so its markers exist to decide who needs less treatment and who needs more: anaplastic cells under the microscope, loss of chromosome pieces 1p and 16q or gain of 1q in the tumour DNA, and, in Europe, how much blastemal tumour survives the pre-operative chemotherapy."@en ;
  schema:url <https://onco.cc/terms/wilms-risk-markers/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/cytogenetics/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/terms/hereditary-cancer-syndromes/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:cancers <https://onco.cc/cancers/wilms-tumor/> .